Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
These revised recommendations of the Advisory Committee on Immunization Practices (ACIP) on measles, mumps, and rubella prevention supersede recommendations published in 1989 and 1990. This statement summarizes the goals and current strategies for measles, rubella, and congenital rubella syndrome (CRS) elimination and for mumps reduction in the United States. Changes from previous recommendations include: Emphasis on the use of combined MMR vaccine for most indications; A change in the recommended age for routine vaccination to 12-15 months for the first dose of MMR, and to 4-6 years for the second dose of MMR; A recommendation that all states take immediate steps to implement a two dose MMR requirement for school entry and any additional measures needed to ensure that all school-aged children are vaccinated with two doses of MMR by 2001; A clarification of the role of serologic screening to determine immunity; A change in the criteria for determining acceptable evidence of rubella immunity; A recommendation that all persons who work in health-care facilities have acceptable evidence of measles and rubella immunity; Changes in the recommended interval between administration of immune globulin and measles vaccination; and Updated information on adverse events and contraindications, particularly for persons with severe HIV infection, persons with a history of egg allergy or gelatin allergy, persons with a history of thrombocytopenia, and persons receiving steroid therapy.
Watson
J C
JC
Hadler
S C
SC
Dykewicz
C A
CA
Reef
S
S
Phillips
L
L
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D004356:Drug Storage; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D008457:Measles / Q000517:prevention & control*; D008458:Measles Vaccine / Q000009:adverse effects / Q000592:standards* / Q000600:supply & distribution; D022542:Measles-Mumps-Rubella Vaccine; D009107:Mumps / Q000517:prevention & control*; D009108:Mumps Vaccine / Q000009:adverse effects / Q000592:standards* / Q000600:supply & distribution; D011247:Pregnancy; D012409:Rubella / Q000517:prevention & control*; D012410:Rubella Syndrome, Congenital / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000009:adverse effects / Q000592:standards* / Q000600:supply & distribution; D014611:Vaccination / Q000592:standards*; D017778:Vaccines, Combined / Q000009:adverse effects / Q000592:standards / Q000600:supply & distribution
D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined